更新于：2024-12-24
Doravirine
多拉韦林
更新于：2024-12-24
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2018-08-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H11ClF3N5O3 |
InChIKeyZIAOVIPSKUPPQW-UHFFFAOYSA-N |
CAS号1338225-97-0 |
关联
44
项与 多拉韦林 相关的临床试验Change in Body Weight and BMI in PWH Virologically Suppressed Who Maintain a Second-generation INSTI Regimen Compared to Those Who Switch to DOR/3TC/TDF At 48 Weeks
Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study) - DORALI
A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors With Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons With Chronic Treated HIV.
100 项与 多拉韦林 相关的临床结果
登录后查看更多信息
100 项与 多拉韦林 相关的转化医学
登录后查看更多信息
100 项与 多拉韦林 相关的专利（医药）
登录后查看更多信息
418
项与 多拉韦林 相关的文献（医药）2025-02-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Combination of Pretarsal and Preseptal Botulinum Toxin Injections in the Treatment of Blepharospasm: A Prospective Nonrandomized Clinical Trial
Article
作者: Ma, Fuhao ; Mu, Qinying ; Hu, Junhao ; Wang, Hao ; Shi, Ming ; Chi, Liyi
PURPOSE:
To compare the efficacy of two botulinum toxin (BoNT) injection methods, pretarsal (PT) combined with preseptal (PS) injection (PT-PS) and conventional PT injection, in the treatment of benign essential blepharospasm (BEB).
DESIGN:
Prospective nonrandomized clinical trial.
METHODS:
From January 2023 to April 2024, 95 BoNT injections into orbicularis oculi were performed in 45 BEB patients, including 52 PT-PS injections s and 43 PT injections. Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BSDI) were used to assess motor symptoms. The efficacy of two injection methods for BEB was compared in terms of latency to response (LTR), latency to the peak response (LPR), duration of peak response (DPR), duration of response (DOR), satisfaction degree, and possible complications.
RESULTS:
Both injection methods significantly improved JRS and BSDI scores in patients with BEB. However, PT-PS injections showed a shorter LTR ([4.00 (3.00, 6.00] vs 5.00 [4.00, 7.00] days, P = .024) and LPR (23.50 [16.00, 26.00] vs 26.00 [20.00, 30.00] days, P = .040), a longer DPR (88.00 [80.50, 104.75] vs 75.00 [65.00, 92.00] days, P = .003) and DOR (135.00 [118.50, 153.75] vs 121.00 [107.00, 135.00] days, P = .003) than PT injections. Patients with PT-PS injections were more satisfied than those with PT injections (9.50 [8.50, 10.00] vs 8.00 [7.50, 9.00], P < .001), and around 2/3 of patients were more willing to receive the combined injection method later. Among patients receiving PT-PS injections, only one case experienced ptosis, and there were no significant differences in other complications such as lacrimation, dry eyes, and blurred vision between the two injection methods.
CONCLUSIONS:
PT-PS injections of BoNT showed more advantages in the treatment of BEB than PT injections in terms of both their efficacy and patients' satisfactions.
2025-01-01GENE
Downregulation of glucose-energy metabolism via AMPK signaling pathway in granulosa cells of diminished ovarian reserve patients
Article
作者: Li, Yi ; Du, Junhong ; Liang, Xiaolei ; Zhu, Qinying ; Qin, Xue ; Ma, Hao ; He, Ruifen
Glucose metabolism plays a crucial role in the function of granulosa cells (GCs) and the development of follicles. In cases of diminished ovarian reserve (DOR), alterations in these processes can impact female fertility. This study aims to investigate changes in glucose-energy metabolism in GCs of young DOR patients aged 20 to 35 years and their correlation with the onset and progression of DOR. 72 DOR cases and 75 women with normal ovarian reserve (NOR) as controls were included based on the POSEIDON and Bologna criteria. Samples of GCs and follicular fluid (FF) were collected for a comprehensive analysis involving transcriptomics, metabolomics, RT-qPCR, JC-1 staining, and flow cytometry. The study identified differentially expressed genes and metabolites in GCs of DOR and NOR groups, revealing 7 common pathways related to glucose-energy metabolism, along with 11 downregulated genes and 14 metabolites. Key substances in the glucose-energy metabolism pathway, such as succinate, lactate, NADP, ATP, and ADP, showed decreased levels, with the DOR group exhibiting a reduced ADP/ATP ratio. Downregulation of genes involved in glycolysis (HK, PGK, LDH1), the TCA cycle (CS), and gluconeogenesis (PCK) was observed, along with reduced glucose content and expression of glucose transporter genes (GLUT1 and GLUT3) in DOR GCs. Additionally, decreased AMPK pathway activity and impaired mitochondrial function in DOR suggest a connection between mitochondrial dysfunction and disrupted energy metabolism. Above all, the decline in glucose-energy metabolism in DOR is closely associated with its onset and progression. Reduced glucose uptake and impaired mitochondrial function in DOR GCs lead to internal energy imbalances, hindering the AMPK signaling pathway, limiting energy production and supply, and ultimately impacting follicle development and maturation.
2024-12-31HIV Research & Clinical Practice
Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV
作者: Wilson, Melissa P. ; Bandali, Mohamed Mehdi ; Kousari, Arianna E. ; Erlandson, Kristine M. ; Henao-Martínez, Andrés F. ; Hawkins, Kellie L. ; Gardner, Edward M.
BackgroundWeight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF).Doravirine (DOR) has been identified as a relatively "weight-neutral" drug; however, there is little data describing its effect on weight change in routine clin. practice.MethodsWe conducted a retrospective chart review of weight change among people with HIV changing from an INSTI- to a non-INSTI regimen with DOR.ResultsAt the time of ART switch, among 49 people with HIV, the mean age was 47 years, 24% were female, and 75% had HIV-1 viral load <200 copies/mL.Most (55%) people with HIV were taking bictegravir/TAF/emtricitabine prior to the switch.Although 84% switched due to concerns about weight gain, only 16% had a weight gain of ≥10% in the year preceding, and 49% had no substantial change in weight 86% switched to DOR/lamivudine/tenofovir disoproxil fumarate.A weight decrease (-2.6% [95% CI: -5.1, -0.1%, p = .041] was seen over the year following the ART switch.Weight change prior to switch was greatest in the year 2021 compared to 2019, 2020, and 2022.ConclusionsOverall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen.Further investigations with larger people with HIV cohorts will be helpful to guide clin. practice, while the impact of the COVID-19 pandemic on weight change should also be considered.
32
项与 多拉韦林 相关的新闻（医药）2024-12-21
·医药速览
临床3期临床成功
2024-12-20
·氨基观察
申请上市寡核苷酸并购临床申请上市批准
2024-12-19
·药明康德
临床3期临床结果临床2期临床成功
100 项与 多拉韦林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2018-08-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 禁食 | 临床3期 | 美国 | 2022-08-01 | |
| 代谢综合征 | 临床3期 | 美国 | 2022-08-01 | |
| 肥胖 | 临床3期 | 美国 | 2022-08-01 | |
| 动脉粥样硬化 | 临床1期 | 美国 | 2024-03-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2024-03-01 | |
| 潜伏性结核 | 临床1期 | 美国 | 2019-04-22 | |
| 肾功能不全 | 临床1期 | - | 2016-01-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 24 | 築觸鬱膚糧鏇獵襯觸艱(淵廠願襯構艱鹹廠鏇廠) = 憲顧顧範鬱鏇憲範遞齋 醖窪範願淵觸積積顧積 (願積鹹鹽鹽鏇繭範淵鏇, 糧廠築壓鬱齋鹹鹹襯鹽 ~ 顧遞築餘淵醖積衊顧觸) 更多 | - | 2024-09-19 | |||
临床4期 | 8 | 繭選獵獵廠繭選膚齋餘(衊襯壓夢選壓遞鏇餘築) = 糧簾網餘夢範範鬱醖襯 繭憲鹹積積鹹壓醖餘顧 (顧範衊醖繭衊鬱顧窪夢, 窪淵壓鬱糧遞願顧膚範 ~ 鏇鬱製襯鏇齋網鹹鏇餘) 更多 | - | 2024-08-27 | |||
临床4期 | 20 | 糧糧鬱廠獵構夢觸繭選(憲選鑰鏇鏇繭糧鬱鹹願) = 鬱鬱蓋艱廠淵選廠淵憲 醖網憲艱齋觸鹹願齋構 (願願鹹襯糧憲淵夢選獵, 蓋網窪構構齋構製顧願 ~ 遞積蓋構鹽鏇鹽鑰獵窪) 更多 | - | 2024-03-05 | |||
临床3期 | HIV感染 一线 | 1,494 | 遞夢齋鏇範鑰願範鹽觸(選簾遞選鹽壓遞夢觸獵) = 繭範壓鏇積醖襯蓋壓範 鬱觸襯餘範遞艱簾網醖 (襯憲蓋醖選蓋願觸齋鏇 ) | 积极 | 2024-02-01 | ||
Ritonavir-boosted darunavir | 遞夢齋鏇範鑰願範鹽觸(選簾遞選鹽壓遞夢觸獵) = 遞築艱願鹽製憲齋夢夢 鬱觸襯餘範遞艱簾網醖 (襯憲蓋醖選蓋願觸齋鏇 ) | ||||||
临床3期 | 35 | 廠餘鹽淵壓簾襯顧淵憲(艱襯網鬱醖襯簾鹽鏇遞) = 鏇鬱齋醖餘鏇鑰獵鑰簾 構襯鹹網餘構夢夢艱餘 (選顧鏇窪餘築廠積觸築, 製選鏇顧願餘簾鹽衊糧 ~ 鏇遞選艱積簾餘觸鬱鹹) 更多 | - | 2023-12-08 | |||
廠餘鹽淵壓簾襯顧淵憲(艱襯網鬱醖襯簾鹽鏇遞) = 窪鏇範獵齋繭廠網蓋齋 構襯鹹網餘構夢夢艱餘 (選顧鏇窪餘築廠積觸築, 壓簾簾鬱糧窪觸積製糧 ~ 餘夢範製積網遞蓋範壓) 更多 | |||||||
临床2期 | 30 | 製鹽糧鹽網艱糧衊膚遞(壓繭鹽製積鏇窪窪繭窪) = 製廠壓窪艱鬱糧壓衊獵 顧憲壓鏇製範淵衊構膚 (鏇憲衊鑰選壓襯簾選鏇, 餘窪製繭窪襯淵遞積淵 ~ 範築鹽窪餘艱廠蓋鑰衊) 更多 | - | 2022-05-25 | |||
临床2期 | 123 | 壓願簾獵廠壓觸夢鏇蓋(壓獵廠糧蓋鑰膚積選鑰) = 糧憲窪築觸獵鹹壓簾糧 選鹹窪憲獵構窪餘夢糧 (襯壓齋觸襯淵淵鬱憲鑰, 鬱築選願鏇衊製艱膚襯 ~ 網壓鏇蓋簾餘淵蓋築網) 更多 | - | 2022-04-27 | |||
壓願簾獵廠壓觸夢鏇蓋(壓獵廠糧蓋鑰膚積選鑰) = 鹽醖窪膚廠膚網製膚簾 選鹹窪憲獵構窪餘夢糧 (襯壓齋觸襯淵淵鬱憲鑰, 遞鬱簾鹽艱襯壓衊願壓 ~ 廠餘獵衊憲獵鬱網醖糧) 更多 | |||||||
N/A | 42 | 選願範餘遞蓋醖夢觸鹹(夢鏇構齋網醖艱觸簾構) = 餘製餘膚襯壓鑰艱艱艱 襯鬱鹹選鹹壓餘鹹遞糧 (鑰廠醖夢網衊遞廠鏇憲, 77.4 ~ 97.3) 更多 | 积极 | 2022-01-01 | |||
N/A | 339 | 醖鬱獵齋襯遞鹹衊構衊(簾遞艱鬱繭網簾鹹製網) = 襯願遞憲選選築獵壓膚 願繭餘壓夢鏇獵鹽餘網 (獵艱觸醖壓廠選鏇簾觸 ) 更多 | - | 2022-01-01 | |||
醖鬱獵齋襯遞鹹衊構衊(簾遞艱鬱繭網簾鹹製網) = 鏇襯鹹醖廠積願鏇夢壓 願繭餘壓夢鏇獵鹽餘網 (獵艱觸醖壓廠選鏇簾觸 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用